Blog

Emmanuel Walckenaer, CEO of Yseop, dives into how medical writers and pharma companies can get started in AI 101: Guide for Medical Writers.

Gartner’s analysis indicates a significant shift in generative AI, moving from rapid growth to stabilization and incremental improvements. At Yseop, we embrace this evolution, continuously enhancing our platform to deliver reliable and efficient AI solutions. Learn how we capitalize on the current phase to drive the future of AI-driven content generation.

In the ever-evolving pharmaceutical landscape, the integration of artificial intelligence (AI) in clinical trials is a game-changer, enhancing efficiency and effectiveness. By exploring the advantages of AI in late-stage drug development, we reveal how AI optimizes clinical trials, streamlines data collection, and improves patient recruitment and retention. Dive in to discover how AI can transform your drug development process and position your organization at the forefront of innovation.

Discover how Yseop, a French start-up, teams up with AWS to revolutionize clinical trials using AI for faster drug development.

Discover the transformative potential of Generative AI in pharmaceuticals. Dive into five essential steps for implementation and investment, from leveraging competitive advantages to ensuring compliance with industry standards. Unveil the future of Pharma innovation with Generative AI.

Emmanuel Walckenaer, CEO of Yseop, dives into how medical writers and pharma companies can get started in AI 101: Guide for Medical Writers.

Tim Martin, Executive VP of Product & Development at Yseop was recently featured in Forbes discussing AI regulation and the EU AI Act.

See how Yseop Copilot is different from other Generative AI technologies across BioPharma and regulated industries.

Generative AI technologies enable the pharmaceutical industry to provide enhanced and quality content automation.